Drug intelligence / Profile preview

levonorgestrel + efavirenz

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Subdermal
01

Overview

Levonorgestrel + efavirenz refers to the co-administration of two pharmaceutical agents with distinct indications and mechanisms. Levonorgestrel is a synthetic progestogen used primarily for emergency contraception and as a component in contraceptive implants. It acts by inhibiting ovulation and altering cervical mucus to prevent fertilization. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination antiretroviral therapy for HIV-1 infection; it inhibits viral replication by binding to and inhibiting the HIV-1 reverse transcriptase enzyme[3]. When administered together, efavirenz induces hepatic enzymes (notably CYP3A4), which accelerates the metabolism of levonorgestrel, leading to significantly reduced plasma concentrations of levonorgestrel[2][5][6][8]. This interaction can compromise contraceptive efficacy. Clinical studies have shown that doubling the dose of levonorgestrel may partially compensate for this reduction but may not fully restore effectiveness in all individuals[4][5][8].

Brand names
AtriplaStocrinSymfi
02

Targets

Human immunodeficiency virus type 1 reverse transcriptasePR (Progesterone receptor)

Beyond the preview

Go deeper on levonorgestrel + efavirenz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levonorgestrel + efavirenz.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call